(别名:阿尔卑利昔、阿博利布、阿哌利西、阿吡利塞、阿培利斯、Alpelisib、PIQRAY、QCR-1、BYL-719、NVP-BYL-719) 阿培利司是一种靶向药物,它可以抑制一种叫做PI3K的酶,这种酶在一些癌细胞中异常激活,导致癌细胞的生长和存活。阿培利司可以与其他药物联合使用,治疗一些携带PIK3CA基因突变的晚期或转移性乳腺癌。 阿...
阿培利司(别名:阿尔卑利昔、阿博利布、阿哌利西、阿吡利塞、阿培利斯、Alpelisib、PIQRAY、QCR-1、BYL-719、NVP-BYL-719)在哪里可以买到? 阿培利司是一种靶向药物,用于治疗携带PIK3CA突变的激素受体阳性、人表皮生长因子受体2阴性 (HR+/HER2-)的晚期或转移性乳腺癌患者。它可以抑制PI3K信号通路,从而抑制肿瘤细胞的...
NVP-BYL719 (a selective inhibitor of the class Ia PI3K isoform alpha) given in the morning is facing on-target tolerability challenge (hyperglycemia) in clinical trials limiting the dose being administered to patient (1). As glucose metabolism is highly impacted by circadian rhythms in patients ...
本发明属于制药技术领域,尤其涉及一种PI3K抑制剂NVPBYL719在制备新型冠状病毒SARSCoV2抑制剂中的应用,体外细胞试验结果表明:该药物能抑制新型冠状病毒SARSCoV2在细胞中增殖.同时在小鼠攻毒试验结果表明:该药物能够有效降低感染小鼠肺部病毒载量,对感染小鼠有明显的治疗作用,可作为新型冠状病毒SARSCoV2抑制剂,用于治疗CO...
Discovery of NVP-BYL719 a potent and selective phosphatidylino- sitol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 2013;23:3741-8.Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, et al. Discovery of NVP-BYL719 a potent and ...
Discovery of NVP-BYL719 a potent and selective phosphatidylino- sitol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 2013;23:3741-8.Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, Fritsch C, Blasco F, Blanz J, Aichholz R, Hamon...
Corrigendum to “Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation” [Bioorg. Med. Chem. Lett. 23 (2013) 3741–3748]doi:10.1016/j.bmcl.2013.06.020Pascal Furet and Vito Guagnano and Robin A. Fairhurst and Patricia Imbach...
Sellers, Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials, Mol. Cancer Ther. 13 (2014) 1117e1129.Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. Characterization ...